When these complexes are given to murines, they cause a lupus-like syndrome (SLE-like) [80]. autoimmune disease in which diverse immunological events can lead to a similar medical picture, characterized by a wide range of medical manifestations and target organs (phenotypes) with unpredictable flares and remissions that eventually lead to long term injury. Sociodemographic factors such as sex, race, and ethnicity play an important part in the incidence of the disease, rate of recurrence of its manifestations, and restorative response. The overall prevalence and incidence of SLE varies from 1.4 to 21.9% and from 7.4 to 159.4 cases per 100,000 people, respectively [1]. SLE can affect several organs and systems, including the bones, skin, brain, heart, lungs, blood vessels, and kidneys. Lupus nephritis (LN) is one of the most severe SLE complications since it is the major predictor of poor prognosis. The incidence and prevalence of LN varies depending on the analyzed human population. The LN cumulative incidence is definitely higher in people of Asian (55%), African (51%), and Hispanic (43%) ancestry compared with Caucasians (14%) (1). Up to 25% of these individuals still develop end-stage renal disease (ESRD) 10 years after onset of renal compromise [2]. In terms of end result, the 5- and 10-yr renal survival rates of LN in the 1990s ranged between 8393% and 7484%, respectively [2]. In addition, LN evolves early in the course of SLE therefore becoming a major predictor of poor prognosis [3]. However, in about 5% of the instances, LN may appear several years after the onset of SLE (i.e., delayed LN) [4]. The group with delayed LN is positively associated with Sjgren syndrome (SS), lung involvement, and antiphospholipid syndrome as compared with ARS-1323 early LN (i.e., those SLE individuals who develop LN during the first 5 years of the disease) [4]. LN has been looked upon like a classic example of immune complex-induced microvascular injury which results from circulating double-stranded DNA polynucleotide antigens/anti-DNA antibody complexes and additional mechanisms includingin situreactivity for free antibodies with fixed antigens and the presence of sensitized T cells which are an important part of the picture [5]. Early deposits of immune complexes (ICs) include nucleosomes, DNA-extractable nuclear antigen antibodies (ENAS), and antibodies against C1q complex of the match system as byproducts of inefficient phagocytosis of apoptotic body. This results in an autoimmune response through epitope development. These ICs have predominance over immunoglobulin G (IgG) 2 and 3. Deposits of ICs are in the beginning located in the glomerular mesangium and interstitial cells within the proximal tubular epithelial cells (PTECs) [5]. These deposited ICs initiate the release of proinflammatory cytokines and chemokines such TSHR as monocyte chemoattractant protein-1 (MCP-1) and cell adhesion molecules (CAMs) thus creating a chronic inflammatory process. The producing overload of the ARS-1323 mesangial phagocytic system prospects to deposits of subendothelial ICs becoming an easy target for monocyte migration and infiltration [5]. This migration and infiltration is due to a general response of the innate immune ARS-1323 system that releases inflammatory proteases therefore causing endothelial injury and proliferation. In turn, the innate immune system response promotes the activation of adaptive immune system secondary to the presence of ICs and dendritic cells (DCs), which consequently result in launch of type 1 interferon and induce maturation and activation of infiltrating T cells. This activation prospects to sequential amplification of T helper 2 lymphocytes, (Th2) T helper 1 (Th1), and T helper 17 (Th17)..